In the previous study, long-term exposure to the CDK4/6 inhibitor palbociclib also demonstrated enhanced antiproliferative effects at lower concentrations, primarily through cytostatic growth inhibition rather than acute cytotoxicity, particularly in estrogen receptor-positive breast cancer cell lines (42). Here, CDK4 is linked to breast carcinoma.